Newswise — HOUSTON ― The third edition of The MD Anderson Manual of Medical Oncology recently was published, offering detailed updates on the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers pioneered by world-leading specialists at The University of Texas MD Anderson Cancer Center.

The textbook reflects the most recent advancements in the evolving area of chemotherapy, targeted therapies and biological and immune therapies of cancer. It emphasizes continuing developments in diagnostic procedures, which include the incorporation of new molecular markers and revised staging systems. It also reinforces how imaging and molecular profiling can help modify and improve upon existing treatment regimens or invasive surgery.

“We believe that this latest edition is of value to any cancer clinician regardless of their career stage,” said Hagop Kantarjian, M.D., chair of Leukemia at MD Anderson. “The textbook is written by our institutional experts in a concise manner, and with strong reliance on tables, figures and pictures that simplify and clarify the diagnostic and therapeutic approaches in cancer. It helps clinicians to quickly assess cancer management options with new information on numerous cancer topics.”

Kantarjian and Robert Wolff, M.D., chair ad interim of General Oncology at MD Anderson, are co-editors of the textbook. Contributors include other MD Anderson faculty and fellows.

The MD Anderson Manual of Medical Oncology includes numerous tables, diagrams, imaging photographs, prescriptive advice, and evidence-based treatment algorithms in the form of flowcharts.

The third edition features new chapters on key topics including pediatric cancers, molecular biomarkers and cancer, immune-oncology, targeted therapies in cancer, onco-cardiology, pulmonary complications of cancer therapy, and applied biostatistics.

The textbook was published by McGraw-Hill Education.